Abclon Inc 174900
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Trading Information
- Previous Close Price
- —
- Day Range
- KRW 16,150.00–16,490.00
- 52-Week Range
- —–—
- Bid/Ask
- KRW 16,230.00 / KRW 16,280.00
- Market Cap
- KRW 266.39 Bil
- Volume/Avg
- 61,352 / 285,166
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 98.04
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Abclon Inc is engaged in the research and development of antibody drugs. Its business sector is divided into Antibody drug and Bio CRO.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Core
- Total Number of Employees
- 58
- Website
- http://www.abclon.com
Comparables
Valuation
|
Metric
|
174900
|
323990
|
310210
|
|---|---|---|---|
Price/Earnings (Normalized) | — | — | — |
Price/Book Value | 13.64 | 4.55 | 12.51 |
Price/Sales | 98.04 | 7,510.76 | 1,079.03 |
Price/Cash Flow | — | — | — |
Price/Earnings
174900
323990
310210
Financial Strength
|
Metric
|
174900
|
323990
|
310210
|
|---|---|---|---|
Quick Ratio | — | — | 4.64 |
Current Ratio | 0.80 | 29.60 | 4.69 |
Interest Coverage | −9.08 | −260.75 | −21.29 |
Quick Ratio
174900
323990
310210
Profitability
|
Metric
|
174900
|
323990
|
310210
|
|---|---|---|---|
Return on Assets (Normalized) | −23.71% | −29.47% | −40.01% |
Return on Equity (Normalized) | −39.44% | −30.90% | −74.90% |
Return on Invested Capital (Normalized) | −26.14% | −33.70% | −42.51% |
Return on Assets
174900
323990
310210
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| Dgyhffvww | Qqfwjr | $124.3 Bil | |||
| Regeneron Pharmaceuticals Inc
REGN
| Pkkgrdn | Kzglbp | $113.1 Bil | |||
| Moderna Inc
MRNA
| Bxkntjjv | Mjfh | $56.9 Bil | |||
| BioNTech SE ADR
BNTX
| Vtjlxbfl | Bqqs | $23.1 Bil | |||
| argenx SE ADR
ARGX
| Vsryzvhqh | Rtst | $23.0 Bil | |||
| Alnylam Pharmaceuticals Inc
ALNY
| Fzymhyn | Ntdkvq | $20.2 Bil | |||
| Biomarin Pharmaceutical Inc
BMRN
| Gxlmfrvyw | Ymvrsxv | $16.1 Bil | |||
| Royalty Pharma PLC Class A
RPRX
| Llblwkdg | Hpwfh | $12.3 Bil | |||
| United Therapeutics Corp
UTHR
| Xzbqkxdv | Shk | $12.2 Bil | |||
| Bio-Techne Corp
TECH
| Jcsjbdlb | Xgmcjz | $12.1 Bil |